X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ALEMBIC LTD SHASUN PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 123.9 122.2 101.4% View Chart
P/BV x 8.5 4.5 188.0% View Chart
Dividend Yield % 0.2 0.2 94.4%  

Financials

 SHASUN PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ALEMBIC LTD
Mar-16
SHASUN PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs9453 178.4%   
Low Rs4629 155.6%   
Sales per share (Unadj.) Rs214.24.7 4,538.0%  
Earnings per share (Unadj.) Rs5.38.8 60.8%  
Cash flow per share (Unadj.) Rs15.89.0 175.7%  
Dividends per share (Unadj.) Rs1.000.15 666.7%  
Dividend yield (eoy) %1.40.4 391.5%  
Book value per share (Unadj.) Rs53.327.7 192.4%  
Shares outstanding (eoy) m56.62267.03 21.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.38.7 3.8%   
Avg P/E ratio x13.14.7 280.0%  
P/CF ratio (eoy) x4.44.6 96.9%  
Price / Book Value ratio x1.31.5 88.5%  
Dividend payout %18.71.7 1,096.2%   
Avg Mkt Cap Rs m3,95810,962 36.1%   
No. of employees `000NANA-   
Total wages/salary Rs m2,164238 909.0%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,1271,260 962.2%  
Other income Rs m229264 86.9%   
Total revenues Rs m12,3561,524 810.7%   
Gross profit Rs m1,00983 1,218.7%  
Depreciation Rs m59461 966.8%   
Interest Rs m4150 138,366.7%   
Profit before tax Rs m230285 80.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 -0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m-736 -1,192.1%   
Profit after tax Rs m3022,343 12.9%  
Gross profit margin %8.36.6 126.7%  
Effective tax rate %-31.72.1 -1,478.6%   
Net profit margin %2.5185.9 1.3%  
BALANCE SHEET DATA
Current assets Rs m6,8841,689 407.7%   
Current liabilities Rs m8,456486 1,739.2%   
Net working cap to sales %-13.095.4 -13.6%  
Current ratio x0.83.5 23.4%  
Inventory Days Days62217 28.4%  
Debtors Days Days10881 132.7%  
Net fixed assets Rs m4,9701,624 306.0%   
Share capital Rs m113534 21.2%   
"Free" reserves Rs m2,8755,960 48.2%   
Net worth Rs m3,0207,404 40.8%   
Long term debt Rs m1,817104 1,742.5%   
Total assets Rs m13,3478,010 166.6%  
Interest coverage x1.6950.7 0.2%   
Debt to equity ratio x0.60 4,271.6%  
Sales to assets ratio x0.90.2 577.5%   
Return on assets %5.429.3 18.4%  
Return on equity %10.031.6 31.6%  
Return on capital %13.331.3 42.6%  
Exports to sales %46.42.9 1,574.7%   
Imports to sales %14.228.9 49.4%   
Exports (fob) Rs m5,62237 15,152.3%   
Imports (cif) Rs m1,728364 475.0%   
Fx inflow Rs m5,84337 15,748.2%   
Fx outflow Rs m2,173365 595.5%   
Net fx Rs m3,669-328 -1,119.3%   
CASH FLOW
From Operations Rs m398346 115.0%  
From Investments Rs m-1,635-48 3,434.9%  
From Financial Activity Rs m1,309-301 -434.8%  
Net Cashflow Rs m71-3 -2,373.3%  

Share Holding

Indian Promoters % 39.2 64.0 61.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.2 1,800.0%  
FIIs % 17.6 9.7 181.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 26.1 151.7%  
Shareholders   20,750 54,701 37.9%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare SHASUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Firm; IT Stocks Gain(09:30 am)

Asian stocks were relatively subdued in the early trade today, with most regional indices hovering around the flat line following the softer lead stateside.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS